KemPharm, Inc. (KMPH): Price and Financial Metrics


KemPharm, Inc. (KMPH): $4.76

0.10 (+2.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KMPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KMPH POWR Grades


  • Value is the dimension where KMPH ranks best; there it ranks ahead of 85.14% of US stocks.
  • KMPH's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • KMPH ranks lowest in Stability; there it ranks in the 5th percentile.

KMPH Stock Summary

  • With a year-over-year growth in debt of -97.56%, Kempharm Inc's debt growth rate surpasses only 1.7% of about US stocks.
  • As for revenue growth, note that KMPH's revenue has grown 131.21% over the past 12 months; that beats the revenue growth of 93.76% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for KMPH comes in at -62.86% -- higher than that of only 6.8% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Kempharm Inc, a group of peers worth examining would be ALBO, EPZM, INFN, KPTI, and RDUS.
  • KMPH's SEC filings can be seen here. And to visit Kempharm Inc's official web site, go to kempharm.com.

KMPH Valuation Summary

  • In comparison to the median Healthcare stock, KMPH's price/earnings ratio is 224.66% lower, now standing at -45.5.
  • KMPH's price/sales ratio has moved NA NA over the prior 78 months.
  • KMPH's price/sales ratio has moved NA NA over the prior 78 months.

Below are key valuation metrics over time for KMPH.

Stock Date P/S P/B P/E EV/EBIT
KMPH 2021-08-31 106.2 23.1 -45.5 -305.7
KMPH 2021-08-30 101.8 22.1 -43.6 -292.3
KMPH 2021-08-27 101.4 22.0 -43.4 -291.2
KMPH 2021-08-26 101.5 22.1 -43.5 -291.6
KMPH 2021-08-25 105.1 22.8 -45.0 -302.2
KMPH 2021-08-24 109.4 23.8 -46.9 -315.3

KMPH Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 66.25%.
  • Its 3 year net cashflow from operations growth rate is now at -154.15%.
  • Its 3 year price growth rate is now at -80.07%.
Over the past 49 months, KMPH's revenue has gone up $28,434,000.

The table below shows KMPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 28.434 10.228 -65.05
2021-06-30 28.394 11.907 -66.3
2021-03-31 23.316 -2.503 -54.746
2020-12-31 13.288 -1.939 -12.76
2020-09-30 12.298 -3.978 -13.941
2020-06-30 21.836 -5.156 -7.869

KMPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KMPH has a Quality Grade of B, ranking ahead of 90.29% of graded US stocks.
  • KMPH's asset turnover comes in at 0.451 -- ranking 100th of 682 Pharmaceutical Products stocks.
  • NAII, ACUR, and EGRX are the stocks whose asset turnover ratios are most correlated with KMPH.

The table below shows KMPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.451 1.000 -0.427
2021-03-31 0.745 1.000 -0.609
2020-12-31 1.218 1.000 -0.410
2020-09-30 1.146 1.081 -0.400
2020-06-30 1.958 1.000 -0.069
2020-03-31 1.318 1.000 -0.222

KMPH Price Target

For more insight on analysts targets of KMPH, see our KMPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.00 Average Broker Recommendation 1.75 (Moderate Buy)

KMPH Stock Price Chart Interactive Chart >

Price chart for KMPH

KMPH Price/Volume Stats

Current price $4.76 52-week high $15.70
Prev. close $4.66 52-week low $4.00
Day low $4.47 Volume 851,200
Day high $5.04 Avg. volume 528,437
50-day MA $4.77 Dividend yield N/A
200-day MA $7.47 Market Cap 163.85M

KemPharm, Inc. (KMPH) Company Bio


KemPharm Inc. provides biopharmaceutical services. The Company offers discovery and development of therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular diseases.


KMPH Latest News Stream


Event/Time News Detail
Loading, please wait...

KMPH Latest Social Stream


Loading social stream, please wait...

View Full KMPH Social Stream

Latest KMPH News From Around the Web

Below are the latest news stories about Kempharm Inc that investors may wish to consider to help them evaluate KMPH as an investment opportunity.

KemPharm selects KP1077 for idiopathic hypersomnia as lead SDX candidate

KemPharm (KMPH) has added ~3.9% in the post-market after announcing the selection of KP1077 for idiopathic hypersomnia ((IH)) as its lead serdexmethylphenidate ((SDX)) candidate in

Seeking Alpha | January 19, 2022

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate Strong Balance Sheet with Cash and Cash Equivalents of $127.8M as of December 31, 2021; Available Cash and Revenues Extend Cash Runway through 2025 and Beyond AZSTARYS® National Launch Accelerating, Full Sales Team in Place by end of January 2022 Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, January 19, 2022, at 4:30 p.m. ET CELEBRATION, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -

Yahoo | January 19, 2022

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET CELEBRATION, Fla., Jan. 12, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, January 19, 2022, at 4:30 p.m. ET, to discuss the Company’s strategy for advancing and expandi

Yahoo | January 12, 2022

KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference

Data highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH CELEBRATION, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that research involving serdexmethylphenidate (SDX), the company’s proprietary prodrug of d-methylphenidate (d-MPH), will be featured in two poster presentati

Yahoo | January 11, 2022

KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”

CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022. Details of the events are as follows: Event: BIO Partnering @ JPMDate: January 10-14, 2022Registration: https://www.bio.org/events/bio-partnering-j

Yahoo | January 6, 2022

Read More 'KMPH' Stories Here

KMPH Price Returns

1-mo 5.54%
3-mo -16.34%
6-mo -43.33%
1-year -51.53%
3-year -80.03%
5-year -92.65%
YTD -45.35%
2021 -22.23%
2020 84.55%
2019 -78.69%
2018 -56.05%
2017 37.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5351 seconds.